Skip to main content
OpenTrials
Completed

NCT Number: NCT02951624

The Effect of Frequency and Duration of Breaks in Sitting Time on Metabolic Cardiovascular Risk Factors

The primary aim of this study is to investigate the acute effect of the frequency and duration of breaks in sitting time on the metabolic risk factor profile.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Center for Physical Activity Research, Copenhagen University Hospital

Copenhagen, 2100, Denmark

About this study

Fifteen (n=15) sedentary adult overweight males will be included in the study. All participants will undergo the four interventions in a randomized cross-over design. Wash out between intervention will be minimum four days.

Control (CON): Participants will be sedentary. Sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching TV, etc.), with a target MET below 1.5 (i.e. 1.5 times REE). Participants will only be allowed to stand or walk to go to the toilet.

Breaker: Participants will be breaking up prolonged sitting with 2 min intervals of low intensity walking.

Intermediate: Participants will be breaking up prolonged sitting with 6 min intervals of low intensity walking

Prolonger: Participants will be breaking up prolonged sitting with 12 min intervals of low intensity walking

All interventions will be matched for total physical activity as well as sitting. Thus, we aim for the active interventions to be iso-caloric.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males, age 20-50 years, waist-to-height ratio ≥ 0.5 and/or waist circumference ≥ 102 cm.

Exclusion criteria

  • Clinically diagnosed diabetes, uncontrolled hypertension, use of glucose- and/or lipid-lowering medication, smoking, evidence of thyroid, liver, lung, heart or kidney disease, non-sedentary occupation, and VO2max levels above the considered average fitness according to age (Shvartz & Reibold 1990), contraindications to increased levels of physical activity.

Treatment and study plan

Control

Behavioral

Control intervention

Breaker

Behavioral

Short breaks of physical activity

Prolonger

Behavioral

longer breaks of physical activity

Intermediate

Behavioral

Intermediate breaks of physical activity

Primary outcomes

  1. AUC post prandial glucose concentration

    Time frame: 6 hours

Secondary outcomes

  1. AUC post prandial insulin concentration

    Time frame: 6 hours

  2. AUC post prandial c-peptide concentration

    Time frame: 6 hours

  3. AUC post prandial triglyceride concentration

    Time frame: 6 hours

  4. AUC post prandial total cholesterol concentration

    Time frame: 6 hours

  5. AUC post prandial ldl concentration

    Time frame: 6 hours

  6. AUC post prandial hdl concentration

    Time frame: 6 hours

  7. AUC post prandial glucagon concentration

    Time frame: 6 hours

  8. Mean 24 hour glucose concentration

    Time frame: 24 hours

  9. Variation in 24 hour glucose concentration

    Time frame: 24 hours

  10. Maximum in 24 hour glucose concentration

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Acronym: BPS2

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Nov 1, 2016
Registry last updated
Dec 14, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.